Docstoc

Pain Management Therapeutics Market to 2017 – Price Competition to Intensify Following Patent Expiries of Lyrica

Document Sample
Pain Management Therapeutics Market to 2017 – Price Competition to Intensify Following Patent Expiries of Lyrica Powered By Docstoc
					Pain Management Therapeutics Market to 2017 – Price Competition to Intensify Following
Patent Expiries of Lyrica and Cymbalta

Global Pain Management Therapeutics Market to Witnesses Moderate Growth as Generic Share
Continues to Rise

In 2010, the global pain management market was worth approximately $28.6 billion,
representing a compound annual growth rate (CAGR) of 5.3% between 2002 and 2010. By 2017,
the global pain management market is estimated to reach $35.1 billion, indicating a CAGR of
3.0% between 2010 and 2017. The major reason behind the decline in the growth rate is the
decline in the annual cost of treating pain in different indications during 2010-2017. Although
the market for management is highly competitive, blockbuster sales of Lyrica (pregabalin) and
Cymbalta (duloxetine HCl) coupled with improved diagnosis of pain indications such as
fibromyalgia and neuropathic pain are expected to drive the market in the future.

The global pain management market is expected to witness a series of patent expiries between
2009 and 2016, which includes some top selling drugs such as Cymbalta, Lyrica and Celebrex
(celecoxib). While the current pain management market has a healthy pipeline and prospects for
growth in the future, these factors will not be able to completely offset the challenge from
generic competition. Therefore, while the pipeline ensures potential for attractive growth in the
long term

The research and development (R&D) pipeline for pain management is moderately healthy due
to the presence of about 282 programs. These programs study drug candidates for the
treatment of neuropathic pain and pain associated with fibromyalgia, cancer, migraine and
osteoarthritis, rheumatoid arthritis, low back pain and post-operative pain.

For Sample Pages, please click or add the below link to your browser:
http://www.gbiresearch.com/RequestSamplePages.aspx?ID=Pain-Management-Therapeutics-
Market-to-2017-Price-Competition-to-Intensify-Following-Patent-Expiries-of-Lyrica-and-
Cymbalta&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report&CompanyID=
dcsto

Nevertheless, the products in the pipeline do not look promising and may not provide better
efficacy and safety levels compared to the drugs currently in the market. The pipeline is a mix of
first-inclass and me-too products. The success of the first-in-class products will determine the
future prospects for the industry. The high level of R&D activity indicates that the pain
management market has potential for growth.

Lyrica (pregabalin) is the branded anticonvulsant product of Pfizer. Lyrica is indicated for the
treatment of epilepsy, fibromyalgia and neuropathic pain. Lyrica, along with Neurontin
(gabapentin), is the first line of therapy for the treatment of neuropathic pain, especially when
tricyclic antidepressants are contraindicated. Lyrica is the only anticonvulsant which has been
approved for the treatment of fibromyalgia. Lyrica generated revenue of $2.6 billion and $2.8
billion for Pfizer in 2008 and 2009 respectively. Eli Lilly’s Cymbalta is another major drug
approved for fibromyalgia, chronic osteoarthritis pain and chronic low back pain. Cymbalta
registered revenue of $2.6 billion and $3 billion in 2008 and 2009 respectively.
GBI Research, the leading business intelligence provider, has released its latest research, “Pain
Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent
Expiries of Lyrica and Cymbalta”, which provides insights into the global pain management
therapeutics market and market forecasts until 2017. The report provides an in-depth analysis
of the top eight therapeutic indications for which pain management medications are prescribed,
including fibromyalgia, neuropathic pain, migraine, cancer pain, osteoarthritis pain, rheumatoid
arthritis pain, low back pain and post-operative pain. The report also examines the global pain
management treatment usage patterns for the covered indications. In addition, the report also
includes insights into the pain management R&D pipeline.

The report is built using data and information sourced from proprietary databases, primary and
secondary research, and in-house analysis by GBI Research’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Pain-Management-Therapeutics-Market-to-2017-
Price-Competition-to-Intensify-Following-Patent-Expiries-of-Lyrica-and-
Cymbalta&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Health
care&CompanyID=dcsto

Visit our report store: http://www.gbiresearch.com

For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe:                 +44 207 753 4299
                        +44 1204 543 533
Asia Pacific:           +91 40 6616 6782

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:21
posted:11/18/2011
language:English
pages:2
Description: Global Pain Management Therapeutics Market to Witnesses Moderate Growth as Generic Share Continues to Rise